Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.153 -0.036 (-3.07%)

Streaming Delayed Price Updated: 2:13 PM EST, Dec 29, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	235,938
Open	1.170
Bid (Size)	1.150 (700)
Ask (Size)	1.160 (700)
Prev. Close	1.190
Today's Range	1.130 - 1.189
52wk Range	0.9400 - 2.230
Shares Outstanding	15,641,611
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

2 Small-Cap Biotechs That Could Reward Patient Investors ↗

December 12, 2025

Via MarketBeat

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy

December 01, 2025

Via Investor Brand Network

Performance

YTD	-18.8%	-18.8%
1 Month	-5.5%	-5.5%
3 Month	-18.8%	-18.8%
6 Month	-17.6%	-17.6%
1 Year	-22.6%	-22.6%

More News

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

December 01, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387

November 17, 2025

Via Investor Brand Network

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

November 17, 2025

Via ACCESS Newswire

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

November 14, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants

November 13, 2025

Via Investor Brand Network

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

November 12, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants

November 11, 2025

Via Investor Brand Network

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

November 11, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC

November 10, 2025

Via Investor Brand Network

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

November 10, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting

November 05, 2025

Via Investor Brand Network

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

November 05, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at Spartan Capital Investor Conference 2025

November 03, 2025

Via Investor Brand Network

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

November 03, 2025

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview

October 29, 2025

Via Investor Brand Network

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

October 29, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston

October 27, 2025

Via Investor Brand Network

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

October 27, 2025

Via ACCESS Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles

October 23, 2025

Via Investor Brand Network

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

October 22, 2025

Via ACCESS Newswire

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

October 20, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387

October 15, 2025

Via Investor Brand Network

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?

Yes, NanoViricides, Inc. Common Stock is publicly traded.

What exchange does NanoViricides, Inc. Common Stock trade on?

NanoViricides, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for NanoViricides, Inc. Common Stock?

The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange

What is the current price of NanoViricides, Inc. Common Stock?

The current price of NanoViricides, Inc. Common Stock is 1.153

When was NanoViricides, Inc. Common Stock last traded?

The last trade of NanoViricides, Inc. Common Stock was at 12/29/25 02:13 PM ET

What is the market capitalization of NanoViricides, Inc. Common Stock?

The market capitalization of NanoViricides, Inc. Common Stock is 18.04M

How many shares of NanoViricides, Inc. Common Stock are outstanding?

NanoViricides, Inc. Common Stock has 18M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.